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Introduction
Intestinal microfold (M) cells are small intestinal epithelial cells localized on the Peyer's patches (PPs) [1] . M cells actively transport luminal antigens from foods, viruses, and bacteria into the PPs, leading to induction of the appropriate immune response [2] .
Because of the role of M cells in antigen transport, targeted delivery of antigens to M cells has recognized as an approach to enhance oral vaccine efficacy [3] . Towards this end, several well-defined cell surface markers on M cells have been investigated as targets to deliver antigens to M cells. Targets investigated to date include α1-2 fucosylated glycans expressed on murine M cells that are recognized by the monoclonal antibody NKM16-2-4 [4] , and glycoprotein 2 (GP2), an M cell specific protein that can be targeted with an anti-GP2 [5, 6] . Oral administration of antigen conjugated to either the NKM16-2-4 or anti-GP2 antibody, greatly elevated serum IgG and intestinal IgA responses, providing a proof of concept for an M cell targeted oral vaccine [4, 5] .
Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a family of proteins that recognize sialic acid residues on glycoproteins and glycolipids [7] . Siglecs were first characterized as immune cell receptors with functions including regulation of cellular activation, tolerance induction, and pathogen recognition and uptake [7] . Recent studies, however, have revealed that several Siglecs are also expressed on non-immune cells, suggesting that Siglecs play roles beyond modulating immune cell responses. For example, Siglec-4 is well known to be expressed primarily on oligodendrocytes of the central nervous system [7] , Siglec-6 in the placenta [8] , Siglec-12 in the prostate and kidney [9] , Siglec-5/14 on amniotic epithelium [10] , and Siglec-5 on human M cells [11] . Due to their restricted expression pattern and efficient endocytic properties, Siglecs remain promising targets for delivering therapeutics to specific immune and non-immune cell types alike [12] .
Siglec-F is a member of the Siglec family and was first identified as an eosinophil marker in mouse [7] . Siglec-F recognizes the NeuAcα2-3Gal[6S]β1-4GlcNAc motif printed on the synthetic glycan microarray [13] , and it is proposed that binding of Siglec-F to a related glycan expressed on mouse lung potentiates eosinophil death in the lung during allergic asthma [14] . Accordingly, Siglec-F deficient mice exhibit increased numbers of lunginfiltrating eosinophils during an asthmatic state [15] . While these studies have established a suppressive function for Siglec-F on eosinophils, the role of Siglec-F in other cell-types, such as alveolar macrophages [16] and activated T cells [15] , remains unclear.
We generated a monoclonal antibody recognizing Siglec-F to investigate its cell type expression and biological roles in mouse tissues and cells. Although attention to expression of Siglec-F has focused on immune cells in blood, spleen, and lymph nodes, we noted a single report of the presence of Siglec-F mRNA in mouse M cells [17] . As described here, we found that Siglec-F protein is indeed expressed on the luminal surface of small intestinal 
Anti-Siglec-F monoclonal antibody generation
The anti-Siglec-F monoclonal antibody (rat IgG2b, clone 9C7) was generated as described previously [18] . Briefly, Lewis rats were immunized with Siglec-F-expressing CHO cells emulsified in complete Freund's adjuvant (Difco Laboratories). Following two boosts of the cells emulsified in incomplete Freund's adjuvant (Difco Laboratories), the immunized rats were sacrificed and the common iliac lymph nodes were harvested to generate hybridomas.
The established hybridomas were screened for reactivity to Siglec-F-CHO cells and Siglec-F-expressing HEK293 cells by flow cytometry. The selected anti-Siglec-F expressing hybridoma was grown for 7-10 days, and the antibody was purified from the culture supernatant and labelled with Alexa Fluor-647 (Life Technologies).
Flow cytometry
PPs were harvested from mouse small intestine and vortexed in PBS vigorously. The supernatant was removed, and this washing step was repeated three times. Washed PPs 
Microscopy
Terminal ileum PPs were harvested from C57BL/6J mice, washed in 1x PBS, snap frozen in OCT (Bright CRYO-M-BED), and cryosectioned at 8-µm thickness. Sections were fixed for 5 min with -20ºC methanol, washed once with PBS containing 0.05% Tween-20 (PBS-T), and washed twice with PBS. All subsequent incubations were performed at RT. Sections were treated with 3% H 2 O 2 in PBS for 30 min. After washing once with PBS-T and twice with PBS, slides were blocked with PBS containing 6% BSA and 10% normal mouse serum (Southern Biotech) for 30 min. Anti-mouse Siglec-F or isotype control (10 µg/ml) and UEA-I-FITC (20 µg/ml) were applied for 60 min. After washing, as described above, sections were incubated for 30 min with mouse anti-rat IgG2b-HRP (Southern Biotech, 2 µg/ml). Sections were washed once with PBS-T, washed four times with 1x PBS, and treated for 5 min with Cy-3 Plus TSA reagent (Perkin Elmer) according to the manufacturer's instructions. After washing once with PBS-T and four times with PBS, sections were incubated with anti-mouse M cell antibody NKM16-2-4 (25 µg/ml). After 60 min the slides were washed and treated with biotinylated anti-rat IgG2c (10 µg/ml) for 30 min, washed, and stained for 20 min with Alexa647 conjugated streptavidin and counterstained with DAPI (5 µg/ml). Sections were imaged with the Zeiss Axio Imager M2, and data were analyzed with ZEN 2 (blue edition).
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Intestinal loop assay
Balb/c mice were anesthetized with a continuous flow of isoflurane. The small intestine was exposed via laparotomy, and an intestinal loop containing PPs was made using threads ( 
Generation of a Siglec-F monoclonal antibody
In order to study Siglec-F expression profile on mouse tissues, we generated a monoclonal antibody to Siglec-F. Briefly, Lewis rats were immunized with Siglec-F expressing CHO cells.
Hybridomas were established by fusing myeloma cell line with the lymphocytes from common iliac lymph nodes of the immunized animals. Hybridoma screening was performed based on the antibody reactivity to Siglec-F expressing CHO cells and HEK293 cells by flow cytometry. The established clone 9C7 produced a rat IgG2b monoclonal antibody, which binds to Siglec-F expressed on HEK293 cells (Fig. 1). 
Expression of Siglec-F on PP M cells

A report showing Siglec-F mRNA expression in mouse M cells [17] motivated us to investigate Siglec-F protein expression on mouse M cells using our Siglec-F monoclonal antibody (clone 9C7). PP M cells were identified as CD45
-UEA-I + NKM16-2-4 + by flow cytometric analysis as reported previously [17] . We found that PP M cells did indeed express
Siglec-F when compared to an isotype control at levels comparable to eosinophils (CD45 + CD11b + CCR3 + ) ( Fig. 2A and B) . Staining of M cells with the antibody clone 9C7 was specific for Siglec-F, since M cells isolated from Siglec-F KO mice stained at levels equivalent to the isotype control (Fig. 2B) . In the immunohistochemical analysis, we found that Siglec-F staining was co-localized with the UEA-I and NKM16-2-4 signals in frozen sections of PP (Fig. 2C) . Of note, Siglec-F expression was observed on the intestinal luminal surface of M cells (Fig 2C, arrows) . Together these data demonstrate that Siglec-F is expressed on the luminal surface of mouse PP M cells.
In vivo M cell targeting by anti-Siglec-F antibody
To test whether M cells are targeted by Siglec-F antibody, Alexa647-labelled antiSiglec-F or the isotype control antibody were injected intraluminally into a small intestine loop created by ligatures (Fig. 3A) . PPs were harvested, and cells were analyzed by flow M A N U S C R I P T
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9 cytometry. We found that the Siglec-F antibody bound to M cells, but not to eosinophilspresumably because the eosinophils are not exposed to the intestinal lumen -demonstrating the potential of M cell targeting through Siglec-F via the intestinal lumen (Fig. 3B) .
Our findings suggest a novel role for Siglec-F in M cells, opening up several key questions to be addressed; a) Since Siglec-F is well documented to have endocytic activity In humans, Siglec-8 is characterized as a functional paralogue of Siglec-F, exhibiting the same expression pattern and glycan-binding specificity [7] . Interestingly, Siglec-5 has been reported to be expressed in human M cells [11] . Therefore, it would of interest to assess whether Siglec-5 and Siglec-F are functional paralogues on M cells. 
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